This bill aims to support the development of medications for rare diseases by improving incentives for drug companies, especially in light of challenges from the COVID-19 pandemic.
Leo's Law This bill extends by 180 days the relevant periods of market exclusivity for drugs for rare diseases or conditions (i. e., orphan drugs) for which applications were submitted during the COVID-19 emergency period.
1. This bill helps encourage the creation of drugs for rare diseases. 2. It addresses challenges caused by the COVID-19 pandemic. 3. The bill aims to improve incentives for drug developers. 4. It focuses on orphan drugs, which are for conditions affecting few people. 5. The bill is currently introduced in the House of Representatives.
This bill affects patients with rare diseases and the companies that develop treatments for them.